Quanterix Corporation (QTRX)

Over the past six months, Quanterix's stock price has been impacted by several events. In January 2026, the company announced a JAMA study highlighting the prognostic value of its Alzheimer's risk profiling and appointed Everett Cunningham as President and CEO. In February 2026, Quanterix submitted a 510(k) premarket notification to the FDA for an Alzheimer's disease blood test. In December 2025, a Nature study redefined Alzheimer's disease neuropathology prevalence. November 2025 saw the release of Q3 2025 financial results, with revenue increasing but gross margin decreasing. In October 2025, Quanterix received an analyst rating upgrade to "Buy" from Zacks. In August 2025, Quanterix reported a Q2 loss and missed revenue estimates. In July 2025, Quanterix completed its acquisition of Akoya Biosciences. The stock has experienced volatility, with its 52-week range between $4.05 and $8.88.

Specific detailed information regarding the demand seasonality for Quanterix Corp.'s products and services is not publicly detailed in the provided search results.

Quanterix Corporation is a life sciences company focused on developing and marketing ultra-sensitive digital immunoassay platforms for precision health in research and diagnostics. Their products and services are based on Simoa technology, enabling the detection of protein biomarkers at low concentrations. Key offerings include instruments like the HD-X, SR-X, and SP-X, consumables such as Simoa Assay Kits, and services like contract research and LDT testing. In 2025, Quanterix acquired Akoya Biosciences, expanding its portfolio to include multiplexed tissue imaging.

Quanterix Corporation has a global geographic footprint, with operations and market presence in North America, Europe, the Middle East, Africa, and the Asia Pacific regions.

In the past year, Quanterix has enhanced its brand reputation through scientific advancements and product developments, particularly in Alzheimer's disease. A JAMA study highlighted the prognostic value of their multi-analyte approach, and a Nature study redefined Alzheimer's disease neuropathology prevalence. The submission of a 510(k) premarket notification to the FDA for an Alzheimer's blood test demonstrates their commitment to diagnostics. Simoa ONE assay kits became compatible with flow cytometers, expanding market reach, and a new dried blood spot extraction kit was launched. The acquisition of Akoya Biosciences and focus on cash flow break-even by 2026 indicate a forward-looking approach.

Institutional investors hold a significant stake in Quanterix Corporation, owning 86.48% of the company's stock as of Q2 2025. Major institutional owners include Portolan Capital Management, LLC, Ameriprise Financial Inc., BlackRock, Inc., and Vanguard Group Inc. Insider ownership was reported at 6.59% as of August 4, 2025.